IDG Contributor Network: Price of entry or corporate strategy: how pharma and biotech are approaching digital health
The high costs of drug discovery and commercialization, looming patent cliffs, and increasing regulatory pressure on drug pricing have created a perfect storm of margin and growth pressures on the pharma sector. In an apparent response to these pressures, M&A activity in pharma is back. This month, Bristol Myers Squibb’s announced its $74 Billion acquisition…